The National Institute for Health and Care Excellence (NICE) Clinical Melanoma Guideline was published in 2015. It was designed to address some areas of controversy in melanoma management and reduce variation in practice across the UK. Strong recommendations were made by the Guideline Development Group (GDG) if the evidence was persuasive (when the words ‘offer’ or ‘do not offer’ were used), and weaker recommendations were made if the evidence was not as strong (when the word ‘consider’ was used). The guideline addressed issues of importance to melanoma patients, from screening in the skin cancer clinic, to the question of whether regular scans should be considered for poorer prognosis patients. It did not address issues of prevention or early detection in primary care. It could not address issues already reviewed by NICE, such as the use of drugs for advanced disease. The guideline made recommendations of relevance to the management of melanoma in secondary and tertiary care – in this article I have chosen to highlight those of particular relevance to dermatological skin cancer clinics, but the whole guideline is relevant. Where the text is as published by NICE, italics are used. The stages of melanoma referred to in the guideline are from the American Joint Committee on Cancer’s Melanoma of the Skin Staging (7th edition).